Litigation Details for Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC (N.D. Ill. 2012)

Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC (N.D. Ill. 2012)

Docket		Date Filed	2012-05-17
Court	District Court, N.D. Illinois	Date Terminated	2015-11-17
Cause	35:271 Patent Infringement	Assigned To	Rebecca R. Pallmeyer
Jury Demand	None	Referred To
Parties	CUMBERLAND PHARMACEUTICALS INC.
Patents	8,148,356; 8,399,445
Attorneys	Elizabeth A.F. Morris
Link to Docket	External link to docket

Details for Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC (N.D. Ill. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-05-17				External link to document

Cumberland Pharmaceuticals v. Mylan Institutional: Acetadote Patent Litigation Summary

Last updated: August 12, 2026

Cumberland Pharmaceuticals defeated Mylan Institutional’s challenge to the Acetadote patent covering the 21-hour intravenous acetylcysteine treatment regimen for acetaminophen overdose. The Federal Circuit affirmed the district court’s judgment that the asserted claims were not invalid for obviousness and that Mylan’s proposed ANDA product infringed. The case is a key precedent on unexpected results, motivation to modify a known treatment protocol, and the evidentiary burden for pharmaceutical obviousness challenges. [1]

What drug and patent were at issue in Cumberland v. Mylan?

The dispute involved Acetadote, Cumberland’s injectable acetylcysteine product used to treat acetaminophen overdose. The product is administered intravenously under a standardized 21-hour protocol consisting of three doses:

Treatment stage	Acetylcysteine dose	Administration period
First dose	150 mg/kg	About 1 hour
Second dose	50 mg/kg	About 4 hours
Third dose	100 mg/kg	About 16 hours
Total	300 mg/kg	21 hours

The asserted patent was U.S. Patent No. 8,399,445, which claims methods for treating acetaminophen overdose using the three-dose, 21-hour intravenous acetylcysteine regimen. The patent issued on March 19, 2013, from an application filed in 2011. Its nominal patent term therefore extended into the early 2030s, subject to applicable patent-term adjustment and any Orange Book listing details. [2]

What did the asserted patent claim?

The claims were directed to a treatment method rather than merely to the acetylcysteine molecule. The patent required administration of acetylcysteine in three specific dosage stages over approximately 21 hours.

The patent was commercially important because acetylcysteine itself was an established antidote. Cumberland’s protection depended on the claimed dosing protocol, the intravenous route, and the timing and amounts of the three administrations.

Why did Mylan file the patent challenge?

Mylan sought FDA approval for a generic acetylcysteine injection through an abbreviated new drug application. As part of the ANDA process, Mylan made a Paragraph IV certification asserting that the ’445 patent was invalid, unenforceable, or would not be infringed by the proposed generic product.

Cumberland filed an infringement action after receiving Mylan’s Paragraph IV notice. The filing triggered the Hatch-Waxman 30-month stay of FDA approval, subject to court rulings and statutory exceptions. [3]

Mylan’s principal invalidity theory was obviousness. The company argued that the claimed 21-hour regimen was an obvious modification of earlier acetylcysteine treatment protocols and that a skilled artisan would have had reason to use the claimed dosing schedule.

What prior art did Mylan rely on?

Mylan relied on earlier clinical literature describing acetylcysteine treatment for acetaminophen overdose. The relevant prior art included protocols using acetylcysteine over longer periods, particularly a 72-hour oral regimen and earlier intravenous treatment approaches.

The Federal Circuit characterized the dispute as turning on whether the prior art supplied a reason to select the claimed 21-hour intravenous regimen and whether the objective evidence demonstrated that the claimed regimen produced unexpected clinical benefits. [1]

The prior art did not make the claimed regimen legally automatic. The existence of earlier treatment protocols established that acetylcysteine therapy was known. It did not, by itself, establish that the specific dosing schedule claimed by Cumberland would have been obvious.

How did the district court rule?

The district court found the asserted claims valid and infringed. It rejected Mylan’s obviousness challenge after considering:

• The differences between the prior-art protocols and the claimed regimen.
• The absence of a sufficient reason to make the specific modifications required by the claims.
• Evidence that the 21-hour regimen reduced treatment time and improved clinical practicality.
• Objective indicia of nonobviousness, including unexpected results and commercial success.
• The relationship between the claimed features and the reported benefits.

The district court concluded that Mylan had not established obviousness by clear and convincing evidence. [1]

Mylan appealed to the U.S. Court of Appeals for the Federal Circuit.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s judgment in Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC, 846 F.3d 1291 (Fed. Cir. 2017). [1]

The appellate court held that the district court properly evaluated the obviousness record and did not clearly err in finding that the claimed regimen was nonobvious.

What was the Federal Circuit’s reasoning?

The Federal Circuit focused on the complete obviousness analysis rather than isolated similarities between the patent claims and the prior art.

The court accepted that the prior art disclosed acetylcysteine treatment and various dosage schedules. That disclosure was not enough to prove that a skilled artisan would have selected the claimed three-dose, 21-hour intravenous regimen with a reasonable expectation of success.

The court also upheld the district court’s treatment of objective evidence. Unexpected results can support patent validity when the evidence is tied to the claimed invention. The record supported the conclusion that the claimed regimen delivered clinically meaningful benefits that were not adequately predicted by the prior art.

The decision applied the Supreme Court’s post-KSR obviousness framework. A patent claim may be obvious even when no prior-art reference contains every limitation in a single document, but the challenger must still show an articulable reason to combine or modify the references and a reasonable expectation of success. [1, 4]

Was Mylan’s ANDA product found to infringe?

Yes. The district court entered a judgment that Mylan’s proposed ANDA product infringed the asserted claims. The Federal Circuit affirmed the judgment.

In Hatch-Waxman litigation, infringement is assessed based on the product described in the ANDA and the proposed labeling, rather than on commercial sales of an already-launched generic. The ruling therefore blocked FDA approval of Mylan’s proposed product for the relevant patent period unless the parties reached a settlement, the patent was later invalidated, or another legal route to approval became available.

What was the Orange Book status of Acetadote?

Acetadote was approved by the FDA as an injectable acetylcysteine product for the treatment of acetaminophen overdose. The relevant patent protection was tied to the treatment method and product labeling rather than to a new molecular entity.

The Orange Book framework can list patents claiming the drug substance, drug product, or approved method of use. Cumberland’s litigation position centered on the patent covering the approved acetylcysteine treatment regimen. FDA listing status can change through patent delisting, expiration, administrative corrections, or later regulatory submissions. [3, 5]

The case did not involve a biosimilar pathway. Mylan pursued an ANDA because acetylcysteine is a small-molecule drug. The applicable competitive threat was generic entry, not biosimilar substitution.

When did the Acetadote patent lose exclusivity?

The asserted ’445 patent had a nominal term extending into the early 2030s based on its 2011 application filing date. The precise enforceable expiration date depends on the patent’s recorded term adjustment and any relevant continuation or terminal-disclaimer information.

The litigation itself did not invalidate the patent. The Federal Circuit’s 2017 decision therefore preserved Cumberland’s ability to enforce the patent against the accused ANDA product during the remaining term.

Separate FDA exclusivities, if applicable to the product’s approval history, would not replace the patent analysis. Regulatory exclusivity and patent exclusivity are different rights with different expiration rules.

Did the case involve a Paragraph IV challenge?

Yes. Mylan’s ANDA filing included a Paragraph IV certification against Cumberland’s patent. Cumberland responded with a patent infringement action, creating the statutory framework for the FDA approval stay.

The Paragraph IV challenge placed the burden on Mylan to establish invalidity or noninfringement in the litigation. The court rejected Mylan’s invalidity theory and found infringement.

What generic launch risks did Mylan face?

Mylan faced several barriers to an immediate launch:

1. A finding of infringement based on the ANDA product.
2. A valid and enforceable asserted patent.
3. The Hatch-Waxman approval stay.
4. Potential exposure to damages if the product were launched before patent expiration.
5. The commercial risk of entering an injectable hospital product market while the patent judgment remained in force.

For Cumberland, the decision reduced the near-term risk of a direct generic competitor to Acetadote’s claimed treatment regimen.

What patent litigation affected Acetadote?

The principal reported litigation involving the case was:

Item	Detail
Plaintiff	Cumberland Pharmaceuticals Inc.
Defendant	Mylan Institutional LLC
District docket	1:12-cv-03846
Technology	Intravenous acetylcysteine treatment for acetaminophen overdose
Asserted patent	U.S. Patent No. 8,399,445
Procedural vehicle	Hatch-Waxman ANDA litigation
Core defense	Obviousness
District-court result	Validity and infringement judgment for Cumberland
Federal Circuit decision	Affirmed
Federal Circuit citation	846 F.3d 1291
Decision year	2017

The Federal Circuit opinion is the controlling appellate authority. Publicly reported decisions associated with the case establish the merits outcome. A separate settlement agreement or license arrangement is not established by the appellate decision and should not be treated as part of the adjudicated holding.

How strong was Cumberland’s Acetadote patent estate?

The asserted patent was strong against the specific challenge presented in the case. Its principal strengths were:

• It covered a clinically adopted dosing regimen.
• The asserted claims included detailed dose and timing limitations.
• Mylan’s prior art showed earlier acetylcysteine protocols but did not compel the claimed regimen.
• Cumberland presented objective evidence supporting nonobviousness.
• The district court’s factual findings received deferential appellate review.
• The Federal Circuit affirmed rather than remanding for a new obviousness analysis.

The estate’s strength was narrower than a composition-of-matter patent. Acetylcysteine was an old active ingredient, so Cumberland could not rely on molecule-level exclusivity. Its protection depended on the enforceability of the method-of-use claims and the extent to which a generic label would practice those claims.

What were the main vulnerabilities?

The patent estate had several structural vulnerabilities:

• The active ingredient was off-patent.
• Earlier acetylcysteine dosing protocols created an obviousness attack.
• Generic manufacturers could seek noninfringing labeling if FDA-approved indications and dosing instructions permitted it.
• Method-of-use patents are exposed to claim-construction disputes over dose ranges, timing, route, and label language.
• Patent expiry would remove the primary barrier to ANDA competition.

The favorable decision reduced those risks but did not create indefinite protection for the product.

Did the case involve formulation patents or manufacturing barriers?

The case was principally a method-of-use dispute. The Federal Circuit decision did not establish a separate, enforceable formulation or manufacturing patent barrier as the basis for the judgment.

Acetylcysteine injectable products may present manufacturing and regulatory challenges, including stability, sterility, concentration control, packaging, and injectable-product quality requirements. Those factors can affect generic entry, but they were distinct from the patent issues resolved in Cumberland v. Mylan.

Did the case involve licensing or a settlement agreement?

The reported appellate decision does not identify a settlement agreement or license as the basis for resolving the dispute. The final adjudicated result was an affirmance of Cumberland’s judgment on validity and infringement.

A settlement could have commercial effects not reflected in the appellate opinion, but the reported court decision should be analyzed as a Cumberland win on the litigated patent claims.

What was the commercial impact of the decision?

The decision protected Cumberland from the specific Mylan ANDA challenge during the remaining enforceable patent term. The commercial value was concentrated in Acetadote’s hospital and emergency-use market, where an approved generic injectable could create rapid price and volume pressure.

The case did not eliminate all competition. It preserved protection against the accused product and against product labeling that practiced the asserted method claims. Other acetylcysteine products, alternative formulations, compounding activity, or later generic strategies could present separate risks depending on FDA approval and patent scope.

Revenue exposure cannot be quantified reliably from the reported opinions alone. The litigation record establishes patent protection and launch delay, not a verified product-revenue figure or damages amount.

What is the competitive landscape after Cumberland v. Mylan?

The competitive landscape has three levels:

Competitive category	Relevance
Acetylcysteine injection generics	Direct threat after patent and regulatory barriers expire or are avoided
Alternative acetylcysteine products	May compete if approved for the relevant indication and dosing use
Other overdose-treatment products	Clinical substitutes are limited because acetylcysteine is the established antidote for acetaminophen toxicity

There is no biosimilar risk because Acetadote is a small-molecule drug. The central post-litigation risk is generic injectable entry, subject to the scope and expiration of the method-of-use patent.

Key Takeaways

• Cumberland Pharmaceuticals litigated U.S. Patent No. 8,399,445 against Mylan’s ANDA for generic acetylcysteine injection.
• The patent covered the 21-hour, three-dose intravenous acetylcysteine regimen for acetaminophen overdose.
• The district court found the patent valid and infringed.
• The Federal Circuit affirmed in 2017 in 846 F.3d 1291.
• Mylan’s main defense was obviousness based on earlier acetylcysteine treatment protocols.
• The court held that the prior art did not establish a sufficient reason and reasonable expectation of success for the claimed regimen.
• The decision protected Cumberland against Mylan’s proposed product during the patent term.
• The case involved generic-entry risk, not biosimilar risk.
• The asserted protection was method-of-use-based, not molecule-based.
• The patent’s nominal term extended into the early 2030s, subject to the official patent-term calculation.

FAQs

What is Cumberland Pharmaceuticals v. Mylan Institutional LLC about?

It is a Hatch-Waxman patent case involving Cumberland’s Acetadote product and Mylan’s proposed generic acetylcysteine injection. The Federal Circuit affirmed Cumberland’s victory on patent validity and infringement.

What patent did Cumberland assert against Mylan?

Cumberland asserted U.S. Patent No. 8,399,445, covering the 21-hour, three-dose intravenous acetylcysteine treatment regimen for acetaminophen overdose.

Did Mylan invalidate the Acetadote patent?

No. The district court rejected Mylan’s obviousness challenge, and the Federal Circuit affirmed that result.

Does Cumberland v. Mylan apply to biologic drugs?

No. The case concerns acetylcysteine, a small-molecule drug. It applies to ANDA-based generic competition, not the biosimilar pathway under the Public Health Service Act.

What is the main legal lesson from the case?

Earlier disclosure of the same active ingredient and related treatment protocols does not automatically make a later dosing regimen obvious. The challenger must show a reason to select the claimed regimen, a reasonable expectation of success, and must address objective evidence such as unexpected results.

References

1. U.S. Court of Appeals for the Federal Circuit. (2017). Cumberland Pharmaceuticals Inc. v. Mylan Institutional LLC, 846 F.3d 1291.
2. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,399,445, Methods for treating acetaminophen overdose.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications.
4. KSR International Co. v. Teleflex Inc., 550 U.S. 398 (2007).
5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.